OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a ...

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related ...

In this article, we will look at the 13 Best Long-Term Penny Stocks to Buy According to Analysts. What are the Fed’s Plans for 2025? On June 18, Société Générale’s Subadra Rajappa appeared on CNBC to ...

GeneDx Holdings Corp. leverages genomics leadership with robust growth, despite recent stock challenges. Click for more on ...

OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.

OPKO Health is witnessing a negative estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its loss has widened from 25 cents to 30 cents per share.

Strategic Agreements: OPKO Health has been active on multiple strategic fronts. In March, the company partnered with Entera Bio to develop a once-daily oral GLP-1/glucagon dual agonist tablet ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and ...

OPKO Health, Inc. (NASDAQ:OPK) has been a large holding of mine for years. There is a love/hate relationship with the stock (definitely more heavily leaning towards the hate).

Weston, Massachusetts Wednesday, June 11, 2025, 12:00 Hrs [IST] ...

About OPKO Health, Inc. OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its ...

WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the creation of a Scientific Advisory Board to provide counsel and ...